Abstract
Dr Jeffrey Weitz chaired the symposium and welcomed Dr Christian Ruff, who discussed and summarised recent results from key trials of new oral anticoagulants (NOACs) in atrial fibrillation (AF) with a focus on edoxaban. Prof Andreas Goette then evaluated the current guidelines for the use of cardioversion in AF treatment and recent findings from NOAC trials. Dr Jack Ansell described the current management strategies for NOACs and the limitations therein, as well as novel reversal strategies for NOACs currently under development. Finally Prof John Camm, co-chair, summed up the use of NOACs as an alternative to warfarin in the prevention of stroke in patients with AF, and closed the meeting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
